Skip to main content
SpringerLink
Log in

Prevention and Treatment of Venous Thromboembolism

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

All patients at moderate to high risk for the development of venous thrombo- embolism should receive prophylaxis. The approaches of proven value include low-dose heparin, low molecular weight heparin, oral anticoagulants and intermittent pneumatic compression.

The use of one of the cited heparin nomograms will ensure that all patients are rapidly brought within the therapeutic range. Because of the varying sensitivities of thromboplastins, each laboratory should establish a therapeutic range using the activated partial thromboplastin time (APTT) which will correspond to 0.2 to 0.4 U/ml of heparin. Constant vigilance and a high level of suspicion are necessary to establish the clinical diagnosis of heparin-induced thrombocytopenia, and to institute appropriate therapy. Physicians should be aware of the sensitivity of the thromboplastin being used in the performance of the International Normalised Ratio (INR). Care must be taken to ensure that patients are maintained within the target therapeutic range for INR (in most cases 2 to 3) by frequent determination of the INR and appropriate adjustments of warfarin dosage.

Low molecular weight heparin is the recommended approach to the initial management of venous thromboembolism where these agents are available.

Patients with an acute episode of venous thromboembolism should receive warfarin therapy for at least 3 months. At the present time it is reasonable to treat the first recurrence with oral anticoagulants for a period of 12 months and indefinitely for more than 1 recurrence.

For selected patients with acute massive pulmonary embolism, thrombolytic therapy with one of the available agents is recommended. However, the role of thrombolytic therapy in patients with proximal venous thrombosis remains unclear. In selected patients with acute venous thromboembolism who have contraindications to anticoagulant therapy or who have objectively documented recurrent disease while on adequate therapy, the insertion of an inferior vena cava filter is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death: the changing mortality in hospitalized patients. JAMA 1986; 255: 2039–42

    Article  PubMed  CAS  Google Scholar 

  2. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 257–70

    Article  Google Scholar 

  3. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933–8

    Article  PubMed  Google Scholar 

  4. Donaldson GA, Williams C, Scanell J, et al. A reappraisal of the application of the Trendelenburg operation to massive fatal embolism. N Engl J Med 1963; 268: 171–4

    Article  PubMed  CAS  Google Scholar 

  5. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227–40

    Article  PubMed  CAS  Google Scholar 

  6. Collins R, Scrimgeour A, Yusef S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162–73

    Article  PubMed  CAS  Google Scholar 

  7. Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet 1986 Jul; II: 143–6

    Article  Google Scholar 

  8. Nicolaides AN, Arcelus J, Belcaro G, et al. Prevention of venous thromboembolism. Int Angiol 1992; 11(3): 151–8

    PubMed  CAS  Google Scholar 

  9. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: a randomized trial. Ann Intern Med 1985; 102: 21–8

    PubMed  CAS  Google Scholar 

  10. Huisman MV, Buller HE, ten Cate JW, et al. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients: the Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823–8

    Article  PubMed  CAS  Google Scholar 

  11. Moser KM, Le Moine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94: 439–44

    PubMed  CAS  Google Scholar 

  12. Huisman MV, Buller HR, ten Cate JW, et al. Management of clinically suspected acute venous thrombosis in outpatients with serial impedance plethysmography in a community hospital setting. Arch Intern Med 1989; 149: 511–3

    Article  PubMed  CAS  Google Scholar 

  13. Kakkar VV, Flanc Howe CT, et al. Natural history of post-operative deep-vein thrombosis. Lancet 1969; II: 230–3

    Article  Google Scholar 

  14. Lagerstedt CI, Fagher BO, Olsson CG, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; II: 515–8

    Article  Google Scholar 

  15. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855–8

    Article  PubMed  CAS  Google Scholar 

  16. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498–502

    Article  PubMed  CAS  Google Scholar 

  17. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism: a clinico-pathological study in injured and burned patients. Br J Surg 1961; 48: 475–89

    Article  PubMed  CAS  Google Scholar 

  18. Mavor GE, Galloway JMD. The iliofemoral venous segment as a source of pulmonary emboli. Lancet 1967; I: 871–4

    Article  Google Scholar 

  19. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88: 819–28

    Article  PubMed  CAS  Google Scholar 

  20. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263: 2753–69

    Google Scholar 

  21. Bone RC. Ventilation/perfusion scan in pulmonary embolism: ‘The emperor is incompletely attired’. JAMA 1990; 263: 2794–5

    Article  PubMed  CAS  Google Scholar 

  22. Seeker-Walker RH. On purple emperors, pulmonary embolism, and venous thrombosis. Ann Intern Med 1983; 98: 1006–8

    Google Scholar 

  23. Stein PD, Hull RD, Saltzman HA, et al. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest 1993; 103(5): 1553–9

    Article  PubMed  CAS  Google Scholar 

  24. Skinner DB, Salzman EW. Anticoagulant prophylaxis in surgical patients. Surg Gynecol Obstet 1967; 125: 741–6

    PubMed  CAS  Google Scholar 

  25. Shephard RM, White HA, Shirkey AL. Anticoagulant prophylaxis of thromboembolism in post-surgical patients. Am J Surg 1966; 112: 698–702

    Article  Google Scholar 

  26. International Multicentre Trial: prevention of fatal postoperative pulmonary embolism by low doses of heparin [editorial]. Lancet 1975; II: 45-64

  27. Coventry MB, Nolan DR, Beckenbaugh RD. ‘Delayed’ prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg Am 1973; 55: 1487–92

    PubMed  CAS  Google Scholar 

  28. Eskeland G, Solheim K, Skhorten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fracture: a controlled clinical trial. Acta Chir Scand 1986; 131: 16–29

    Google Scholar 

  29. Kakkar V, Stamatakis JD, Bentley PG, et al. Prophylaxis for postoperative deep-vein thrombosis. JAMA 1979; 241: 39–42

    Article  PubMed  CAS  Google Scholar 

  30. Anderson FA, Wheeler HB, Goldberg RJ, et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 581–95

    Google Scholar 

  31. Bergqvist D. Prevention of postoperative deep vein thrombosis in Sweden: results of a survey. World J Surg 1980; 4: 489–95

    Article  PubMed  CAS  Google Scholar 

  32. Laverick MD, Croak SA, Mollan RA. Orthopedic surgeons and thromboprophylaxis. BMJ 1991; 303(6802): 549–50

    Article  PubMed  CAS  Google Scholar 

  33. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg 1980; 191: 207–18

    Article  PubMed  CAS  Google Scholar 

  34. Hull R, Hirsh J, Sackett DL, et al. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127: 990–5

    PubMed  CAS  Google Scholar 

  35. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203–8

    Article  PubMed  CAS  Google Scholar 

  36. Bergqvist D, Matzsch T, Jendteg S, et al. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand 1990; 556 Suppl.: 36–41

    CAS  Google Scholar 

  37. Hauch Kyattar SC, Jorensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17 Suppl.3: 280–3

    Google Scholar 

  38. Eriksson BI, Kalebo P, Ekman S, et al. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393 (Revasc), Ciba, compared to unfractionated heparin [abstract]. Circulation 1994; 90: L596

    Google Scholar 

  39. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385–9

    Article  PubMed  CAS  Google Scholar 

  40. Cook DJ, Guyatt GH, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1995; 108(4): 227S–30S

    Article  PubMed  CAS  Google Scholar 

  41. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954–8

    Article  PubMed  CAS  Google Scholar 

  42. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543–8

    Article  PubMed  CAS  Google Scholar 

  43. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259–65

    Article  PubMed  CAS  Google Scholar 

  44. Kakkar VV, Murray WJG. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786–91

    Article  PubMed  CAS  Google Scholar 

  45. Bergqvist D, Matzsch T, Brumark U, et al. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888–91

    Article  PubMed  CAS  Google Scholar 

  46. Samama M, Bernard P, Bonnardot JP, et al. Low-molecular-weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988; 75: 128–31

    Article  PubMed  CAS  Google Scholar 

  47. European Fraxiparin Study Group. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058–63

    Article  Google Scholar 

  48. Caen JP. A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep-vein thrombosis in general surgery: a French multicentre trial. Thromb Haemost 1988; 59: 216–20

    PubMed  CAS  Google Scholar 

  49. Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of peri-operative deep vein thrombosis in general surgery: a multi-centre double-blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991; 78: 412–6

    Article  Google Scholar 

  50. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925–9

    Article  PubMed  CAS  Google Scholar 

  51. Tørholm C, Broeng L, Jørgensen PS, et al. Thrombo-prophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J Bone Joint Surg Br 1991; 73-B: 434–8

    Google Scholar 

  52. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand 1991; 62(1): 33–8

    Article  PubMed  CAS  Google Scholar 

  53. Danish Enoxaparin Study Group. Low-molecular weight heparin (enoxaparin) vs dextran 70. Arch Intern Med 1991; 151: 1621–4

    Article  Google Scholar 

  54. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114(7): 545–51

    PubMed  CAS  Google Scholar 

  55. Eriksson BI, Kälebo P, Anthmyr BA, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1991; 73-A(4): 484–93

    Google Scholar 

  56. Planes A, Vochelle N, Fagola M, et al. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anesthesia. J Bone Joint Surg Br 1991; 73-B: 418–23

    Google Scholar 

  57. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg Am 1994; 76-A(1): 3–14

    Google Scholar 

  58. Hull RD, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370–6

    Article  PubMed  CAS  Google Scholar 

  59. Lederc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery — a randomized, double-blind trial comparing a low-molecular-weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67(4): 417–23

    Google Scholar 

  60. Lederc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty — a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to warfarin. Ann Intern Med 1996; 124(7): 619–26

    Google Scholar 

  61. Heit J, Berkowitz S, Bona R, et al. Efficacy and safety of Normiflow (a LMWH) compared to warfarin for prevention of venous thromboembolism following total knee replacement: a double-blind, dose-ranging study [abstract]. Thromb Haemost 1995; 73(6): A739

    Google Scholar 

  62. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low molecular weight heparin in the prophylaxis of venous thrombosis: a meta-analysis. Lancet 1992; 340: 152–6

    Article  PubMed  CAS  Google Scholar 

  63. Anderson DR, O’Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119(11): 1105–12

    PubMed  CAS  Google Scholar 

  64. O’Brien BJ, Anderson DR, Goeree, R. Cost-effectiveness of enoxparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994; 150(7): 1083–9

    Google Scholar 

  65. Gallus A, Cade J, Ockelford P, et al. Orgaran (Org 10172) or heparin for preventing venous thromboembolism after elective surgery for malignant disease? A double-blind, randomized multicentre comparison. Thromb Haemost 1993; 70: 562–7

    PubMed  CAS  Google Scholar 

  66. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in hip fracture patients: a prospective randomized comparative study between ORG 10172 and dextran. Surgery 1991; 109: 617–22

    PubMed  CAS  Google Scholar 

  67. Gerhart TN, Yett HS, Robertson LK, et al. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep vein thrombosis in patients who are operated on for fracture of the hip: a prospective, randomized trial. J Bone Joint Surg Am 1991; 73-A(4): 494–502

    Google Scholar 

  68. Hoek J, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by a low-molecular-weight heparinoid. Thromb Haemost 1992; 67 Suppl.: 28

    PubMed  CAS  Google Scholar 

  69. Francis CW, Pellegrini VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992; 267(21): 2911–5

    Article  PubMed  CAS  Google Scholar 

  70. Paiement F, Wessinger SJ, Waltman WC, et al. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987; 2: 23–6

    Article  PubMed  CAS  Google Scholar 

  71. Kaempffe FA, Lifeso RM. Meinking Intermittent pneumatic compression versus Coumadin: prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res 1991; 269: 89–97

    PubMed  Google Scholar 

  72. Powers PJ, Gent M, Jay R, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149: 771–4

    Article  PubMed  CAS  Google Scholar 

  73. Poller L, McKernan A, Thomson JM, et al. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987; 285: 1309–12

    Article  Google Scholar 

  74. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423–8

    PubMed  CAS  Google Scholar 

  75. Dale C, Gallus A, Wycherley A, et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ 1991; 303: 224

    Article  PubMed  CAS  Google Scholar 

  76. Roberts VC, Sabri S, Beely AH, et al. The effect of intermittently applied external pressure on the hemodynamics of the lower limb in man. Br J Surg 1972; 59: 233–6

    Article  Google Scholar 

  77. Turpie AGG, Gallus A, Beattie WS, et al. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 1977; 27: 435–8

    Article  PubMed  CAS  Google Scholar 

  78. Turpie AG, Delmore T, Hirsh J, et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thromb Res 1979; 16: 611–6

    Article  Google Scholar 

  79. Skillman JJ, Collins RR, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery 1978; 83: 354–8

    PubMed  CAS  Google Scholar 

  80. Hull RD, Raskob G, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263: 2313–7

    Article  PubMed  CAS  Google Scholar 

  81. Hull RD, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16: 37–45

    Article  PubMed  CAS  Google Scholar 

  82. Mckenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ 1980; 1: 514–7

    Article  Google Scholar 

  83. Bradley JG, Krugener GH, Jager HJ. The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty. J Arthroplasty 1993; 8(1): 57–61

    Article  PubMed  CAS  Google Scholar 

  84. Santori FS, Vitullo A, Stopponi M, et al. Prophylaxis against deep-vein thrombosis in total hip replacement. J Bone Joint Surg Br 1994; 76-B: 579–83

    Google Scholar 

  85. Fordyce MJF, Ling RSM. A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg Br 1992; 74-B: 45–9

    Google Scholar 

  86. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. Br J Obstet Gynaecol 1984; 91: 588–91

    Article  PubMed  CAS  Google Scholar 

  87. Ishak MA, Moreley KD. Deep venous thrombosis after total hip arthroplasty: a prospective controlled study to determine the prophylactic effect of graded pressure stockings. Br J Surg 1981; 68: 429–32

    Article  PubMed  CAS  Google Scholar 

  88. Allan A, Williams JT, Bolton JP, et al. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983; 70: 172–4

    Article  PubMed  CAS  Google Scholar 

  89. Wells PS, Lensing AWA, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. Arch Intern Med 1994; 154: 67–72

    Article  PubMed  CAS  Google Scholar 

  90. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy — III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46

    Article  Google Scholar 

  91. Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995; 108(4): 312S–34S

    Article  PubMed  CAS  Google Scholar 

  92. Cairns JA, Lewis HD, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995; 108(4): 380S–400S

    Article  PubMed  CAS  Google Scholar 

  93. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders. Chest 1995; 108(4): 444S–55S

    Article  PubMed  CAS  Google Scholar 

  94. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161–82

    Article  PubMed  CAS  Google Scholar 

  95. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing consideration, monitoring, efficacy, and safety. Chest 1995; 108(4): 258S–75S

    Article  PubMed  CAS  Google Scholar 

  96. Colvin Barrowcliffe TW. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992. 2nd rev. J Clin Pathol 1993; 46: 97–103

    Article  Google Scholar 

  97. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691–5

    Article  PubMed  CAS  Google Scholar 

  98. Moser KM. Venous thromboembolism. Am Rev Respir Dis 1990; 141: 235–49

    PubMed  CAS  Google Scholar 

  99. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; II: 1293–6

    Article  Google Scholar 

  100. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260–4

    Article  PubMed  CAS  Google Scholar 

  101. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986, 315: 1109–14

    Article  PubMed  CAS  Google Scholar 

  102. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. Ann Intern Med 1993; 119: 874–81

    PubMed  CAS  Google Scholar 

  103. Brandjes DPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485–9

    Article  PubMed  CAS  Google Scholar 

  104. Brill-Edwards P, Ginsberg S, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104–9

    PubMed  CAS  Google Scholar 

  105. Fennerty A, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ 1985; 290: 27–8

    Article  PubMed  CAS  Google Scholar 

  106. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep-venous thrombosis. Arch Intern Med 1988; 148: 1321–5

    Article  PubMed  CAS  Google Scholar 

  107. Cruickshank MK, Levine MN, Hirsh J, et al. A standard nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333–7

    Article  PubMed  CAS  Google Scholar 

  108. Hull RD, Raskob GE, Rosenbloom DR, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589–95

    Article  PubMed  CAS  Google Scholar 

  109. Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986; 173-86

  110. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1–34

    PubMed  CAS  Google Scholar 

  111. Boshkov LK, Warkentin TE, Hayward CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322–8

    Article  PubMed  CAS  Google Scholar 

  112. Kelton JG, Sheridan D, Brian H, et al. Clinical usefulness of testing for a heparin-dependent platelet aggregation factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103: 606

    PubMed  CAS  Google Scholar 

  113. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734–6

    PubMed  CAS  Google Scholar 

  114. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344–50

    PubMed  CAS  Google Scholar 

  115. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the [14C]serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995 Dec; 104(6): 648–54

    PubMed  CAS  Google Scholar 

  116. Kelton JG. The laboratory diagnosis of heparin-induced thrombocytopenia: still a journey, not yet a destination [editorial]. Am J Clin Pathol 1995 Dec; 104(6): 611–3

    PubMed  CAS  Google Scholar 

  117. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991; 78: 2194–97

    PubMed  CAS  Google Scholar 

  118. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554–61

    PubMed  CAS  Google Scholar 

  119. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1–17

    PubMed  CAS  Google Scholar 

  120. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–88

    Article  PubMed  CAS  Google Scholar 

  121. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441–5

    Article  PubMed  CAS  Google Scholar 

  122. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low-molecular-weight-heparin versus subcutaneous un-fractionated heparin in the treatment of deep vein thrombosis: a Polish multicentre trial. Thromb Haemost 1992; 68: 14–8

    PubMed  CAS  Google Scholar 

  123. Simonneau G, Charbonnier Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541–6

    Article  PubMed  CAS  Google Scholar 

  124. Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994; 72: 186–90

    PubMed  CAS  Google Scholar 

  125. Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601–7

    Article  PubMed  CAS  Google Scholar 

  126. Kuijer PMM, Gallus AS, Cade JF, et al. Randomized comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism [abstract]. Thromb Haemost 1995; 73(6): 288

    Google Scholar 

  127. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682–7

    Article  PubMed  CAS  Google Scholar 

  128. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in te hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81

    Article  PubMed  CAS  Google Scholar 

  129. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32: 196–209

    PubMed  CAS  Google Scholar 

  130. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(4): 231S–46S

    Article  PubMed  CAS  Google Scholar 

  131. Clouse LH, Comp PC. The regulation of haemostasis: the protein system. N Engl J Med 1986; 314: 1298–304

    Article  PubMed  CAS  Google Scholar 

  132. O’Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation 1968; 38: 169–77

    Article  PubMed  Google Scholar 

  133. Wells PS, Holbrook AM, Crowther R, et al. Warfarin and its drug/food interactions: a critical appraisal of the literature. Ann Intern Med 1994; 121: 676–83

    PubMed  CAS  Google Scholar 

  134. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676–81

    Article  PubMed  CAS  Google Scholar 

  135. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873–6

    Google Scholar 

  136. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661–5

    Article  PubMed  CAS  Google Scholar 

  137. Hyers TN, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108(4): 335S–51S

    Article  PubMed  CAS  Google Scholar 

  138. Barritt DW, Jordon SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; I: 1309–12

    Article  Google Scholar 

  139. Sevitt S, Gallagher NG. Venous thrombosis and pulmonary embolism: a clinicopathologic study in injured and burned patients. Br J Surg 1961; 48: 475–89

    Article  PubMed  CAS  Google Scholar 

  140. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855–8

    Article  PubMed  CAS  Google Scholar 

  141. Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism: report of the WHO/International Society and Federation of Cardiology Task Force. JAMA 1992; 268: 1727–33

    Article  PubMed  CAS  Google Scholar 

  142. Goldhaber SZ. Thrombolytic therapy in venous thromboembolism: clinical trials and current indications. Clin Chest Med 1995; 16(2): 307–20

    PubMed  CAS  Google Scholar 

  143. Markel A, Manzo RA, Strandness Jr E. The potential role of thrombolytic therapy in venous thrombosis. Arch Intern Med 1992; 152: 1265–7

    Article  PubMed  CAS  Google Scholar 

  144. Molina JE, Hunter DW, Yedlicka JW, et al. Thrombolytic therapy for postoperative pulmonary embolism. Am J Surg 1992; 163: 375–81

    Article  PubMed  CAS  Google Scholar 

  145. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973; 47 Suppl. II: 1-108

  146. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. BMJ 1974; 1: 343–7

    Article  PubMed  CAS  Google Scholar 

  147. Ly B, Arnesen H, Eie H, et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465–70

    Article  PubMed  CAS  Google Scholar 

  148. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990; 97: 528–33

    Google Scholar 

  149. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473–9

    Article  PubMed  CAS  Google Scholar 

  150. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: al-teplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicentre Study 2. J Am Coll Cardiol 1992; 20: 520–6

    Article  PubMed  CAS  Google Scholar 

  151. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842–5

    Article  PubMed  CAS  Google Scholar 

  152. Sharma GVRK, Folland ED, Mclntyre KM, et al. Longterm hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease [abstract]. J Am Coll Cardiol 1990; 15: 65A

    Article  Google Scholar 

  153. Urokinase-Streptokinase Embolism Trial: phase 2 results. JAMA 1974; 229: 1606-13

    Google Scholar 

  154. UKEP Study Research Group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J 1987; 8: 2–10

    Google Scholar 

  155. Verstraete M, Miller GAH, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353–60

    Article  PubMed  CAS  Google Scholar 

  156. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicentre trial. J Am Coll Cardiol 1992; 20: 24–30

    Article  PubMed  CAS  Google Scholar 

  157. Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest 1992; 101 Suppl.4: 183S–5S

    PubMed  CAS  Google Scholar 

  158. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol 1992; 19: 246–7

    Article  PubMed  CAS  Google Scholar 

  159. King JN, Champlin AM, Ashby RN. Vena cava filters. West J Med 1992; 156: 295–6

    PubMed  CAS  Google Scholar 

  160. Grassi CJ. Inferior vena cavai filters: analysis of five currently available devices. AJR — Am J Roent 1991; 156: 813–21

    CAS  Google Scholar 

  161. Thery C, Asseman P, Amrouni N, et al. Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis. Eur Heart J 1990; 11: 334–41

    PubMed  CAS  Google Scholar 

  162. Greenfield LJ. Evolution of venous interruption for pulmonary thromboembolism. Arch Surg 1992; 127: 622–6

    Article  PubMed  CAS  Google Scholar 

  163. Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. Clin Chest Med 1995; 16(2): 295–305

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Calgary General and Foothills Hospitals, University of Calgary, F6-841 Centre Avenue East, Calgary, Alberta, T2E 0A1, Canada

    Graham F. Pineo & Russell D. Hull

Authors
  1. Graham F. Pineo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell D. Hull
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pineo, G.F., Hull, R.D. Prevention and Treatment of Venous Thromboembolism. Drugs 52, 71–92 (1996). https://doi.org/10.2165/00003495-199652010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652010-00006

Keywords

Search

Navigation